

Zydus receives final approval for Mycophenolate Mofetil Injection & Donepezil Hydrochloride Tablets

06 September 2017 | News

Both the drugs will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad



Zydus Cadila has received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants.

It has also received an approval to market Donepezil Hydrochloride Tablets, in the strength of 23 mg. The drug is indicated for the treatment of dementia of the Alzheimer's disease.

Both the drugs will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.